This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Backeljauw, P. F. Articles by Underwood, L. E. Search for Related Content PubMed PubMed Citation Articles by Backeljauw, P. F. Articles by Underwood, L. E.

Therapy for 6.5–7.5 Years with Recombinant Insulin-Like Growth Factor I in Children with Growth Hormone Insensitivity Syndrome: A Clinical Research Center Study¹

Department of Pediatrics (L.E.U.), Division of Endocrinology, University of North Carolina, Chapel Hill, North Carolina 27599; and Children’s Hospital Medical Center (P.F.B.), Cincinnati, Ohio 45229

Address all correspondence and requests for reprints to: Philippe F. Backeljauw, Division of Pediatric Endocrinology, Department of Pediatrics, Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229-3039.

Eight children with GH insensitivity syndrome were treated with recombinant human insulin-like growth factor I (IGF-I) (80–120 µg/kg sc twice daily) for 6.5–7.5 yr. We previously reported that height velocity (HV) improved with treatment (from mean pretreatment HV of 4.0 cm/yr), to 9.3 cm/yr for the first year and 6.2 cm/yr for the second year. HV remained slightly below this during the subsequent years (mean HV: 5.4, 5.5, 5.2, and 4.8 cm/yr during years 3–6). Mean height SD score before therapy was -5.6; and it improved to -4.5, -4.4, and -4.2 after 2, 4, and 6 yr of therapy, respectively. Treatment was accompanied by gain in body weight and fat. Bone age advanced normally in the prepubertal patients, but it advanced more rapidly during the latter years of treatment in those patients undergoing pubertal changes. The growth of spleen and kidneys (determined by ultrasound) was rapid in the first 2–3 yr of therapy. More age- appropriate growth ensued, but six patients had a renal length for height more than 2 SD above the mean at 6–7 yr of treatment. No major adverse changes in biochemical profile were observed. IGF-I-related hypoglycemia occurred early in treatment with the younger patients, but this problem abated as treatment was continued. IGF-I therapy is effective in promoting statural growth in GH insensitivity syndrome patients, but the growth response is neither as intense nor as well-sustained as the growth response to GH among children with GH deficiency.

This article has been cited by other articles:

				P. F. Collett-Solberg, M. Misra, and on behalf of the Drug and Therapeutics Committee o The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 10 - 18. [Abstract] [Full Text] [PDF]

				R. G Rosenfeld IGF-I therapy in growth disorders Eur. J. Endocrinol., August 1, 2007; 157(suppl_1): S57 - S60. [Abstract] [Full Text] [PDF]

				S. D. Chernausek, P. F. Backeljauw, J. Frane, J. Kuntze, L. E. Underwood, and for the GH Insensitivity Syndrome Collaborative Gr Long-Term Treatment with Recombinant Insulin-Like Growth Factor (IGF)-I in Children with Severe IGF-I Deficiency due to Growth Hormone Insensitivity J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 902 - 910. [Abstract] [Full Text] [PDF]

				C. Camacho-Hubner, S. Rose, M. A. Preece, M. Sleevi, H. L. Storr, F. Miraki-Moud, F. Minuto, J. Frystyk, A. Rogol, G. Allan, et al. Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1246 - 1253. [Abstract] [Full Text] [PDF]

				P. G Voorhoeve, E. F C van Rossum, S. J te Velde, J. W Koper, H. C G Kemper, S. W J Lamberts, and H. A D.-v. de Waal Association between an IGF-I gene polymorphism and body fatness: differences between generations. Eur. J. Endocrinol., March 1, 2006; 154(3): 379 - 388. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				Z. Laron Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003 J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1031 - 1044. [Abstract] [Full Text] [PDF]